Comparative metabolomics profiling of engineered Saccharomyces cerevisiae lead to a strategy that improving β-carotene production by acetate supplementation
- PMID: 29161329
- PMCID: PMC5697841
- DOI: 10.1371/journal.pone.0188385
Comparative metabolomics profiling of engineered Saccharomyces cerevisiae lead to a strategy that improving β-carotene production by acetate supplementation
Abstract
A comparative metabolomic analysis was conducted on recombinant Saccharomyces cerevisiae strain producing β-carotene and the parent strain cultivated with glucose as carbon source using gas chromatography-mass spectrometry (GC-MS), high performance liquid chromatography-mass spectrometry (HPLC-MS) and ultra-high performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) based approach. The results showed that most of the central intermediates associated with amino acids, carbohydrates, glycolysis and TCA cycle intermediates (acetic acid, glycerol, citric acid, pyruvic acid and succinic acid), fatty acids, ergosterol and energy metabolites were produced in a lower amount in recombinant strain, as compared to the parent strain. To increase β-carotene production in recombinant strain, a strategy that exogenous addition of acetate (10 g/l) in exponential phase was developed, which could enhance most intracellular metabolites levels and result in 39.3% and 14.2% improvement of β-carotene concentration and production, respectively, which was accompanied by the enhancement of acetyl-CoA, fatty acids, ergosterol and ATP contents in cells. These results indicated that the amounts of intracellular metabolites in engineered strain are largely consumed by carotenoid formation. Therefore, maintaining intracellular metabolites pool at normal levels is essential for carotenoid biosynthesis. To relieve this limitation, rational supplementation of acetate could be a potential way because it can partially restore the levels of intracellular metabolites and improve the production of carotenoid compounds in recombinant S. cerevisiae.
Conflict of interest statement
Figures
References
-
- Sandmann G. Carotenoid biosynthesis in microorganisms and plants. Eur J Biochem. 1994; 223:7–24. doi: 10.1111/j.1432-1033.1994.tb18961.x - DOI - PubMed
-
- Jaswir I. Carotenoids: sources, medicinal properties and their application in food and nutraceutical industry. J Med Plant Res. 2011; 5: 7119–7131. doi: 10.5897/JMPRx11.011 - DOI
-
- Ajikumar PK, Tyo K, Carlsen S, Mucha O, Phon TH, Stephanopoulos G. Terpenoids: opportunities for biosynthesis of natural product drugs using engineered microorganisms. Mol Pharm. 2008; 5: 167–190. doi: 10.1021/mp700151b - DOI - PubMed
-
- Lee P, Schmidtdannert C. Metabolic engineering towards biotechnological production of carotenoids in microorganisms. Appl Microbiol Biotechnol. 2002; 60: 1–11. doi: 10.1007/s00253-002-1101-x - DOI - PubMed
-
- Zhao J, Li Q, Sun T, Zhu X, Xu H, Tang J, et al. Engineering central metabolic modules of Escherichia coli for improving β-carotene production. Metab Eng. 2013; 17: 42–50. doi: 10.1016/j.ymben.2013.02.002 - DOI - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
